



Declaration for Patent Application English Language Declaration		Attorney Docket No.	LUD 5780.2 US	
		First Named Inventor	Wenbin Ma	
		COMPLETE IF KNOWN:		
<input type="checkbox"/> Submitted with initial filing	<input checked="" type="checkbox"/> Submitted after initial filing (surcharge required 37 CFR 1.16(e))	Application No.	10/670,472	
		Filing Date	September 26, 2003	
		Art Unit	1645	
		Examiner	Not Yet Assigned	

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF

the specification of which

☐ is attached hereto
OR
☒ was filed on 09/26/2003
as United States Application No. or PCT International Application No. 10/670,472
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign applications(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's right certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Application(s)			Priority Not	Certified Copy	
				YES	NO
_____	(Country)	(Filing Date)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Filing Date)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Filing Date)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional prior foreign applications are listed on a supplemental data sheet attached hereto.

Full name of third inventor
Thierry BOON-FALLEUR
Third inventor's signature

Date

Residence
Brussels, Belgium
Citizenship Belgium
Mailing Address
Avenue Hippocrate 74
UCL 7459
B-1200 Brussels
BELGIUM

Full name of fourth inventor, if any
Catherine GERMEAU
Fourth inventor's signature

Date 27.04.2004

Residence
Brussels, Belgium
Citizenship Belgium
Mailing Address
Avenue Hippocrate 74
UCL 7459
B-1200 Brussels
BELGIUM

Full name of fifth inventor, if any
Pierre COULIE
Fifth inventor's signature

Date

Residence
Brussels, Belgium
Citizenship Belgium
Mailing Address
Avenue Hippocrate 74
UCL 7459
B-1200 Brussels
BELGIUM



Declaration for Patent Application English Language Declaration		Attorney Docket No.	LUD 5780.2 US	
		First Named Inventor	Wenbin Ma	
		COMPLETE IF KNOWN:		
<input type="checkbox"/> Submitted with initial filing	<input checked="" type="checkbox"/> Submitted after initial filing (surcharge required 37 CFR 1.16(e))	Application No.	10/670,472	
		Filing Date	September 26, 2003	
		Art Unit	1645	
		Examiner	Not Yet Assigned	

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF

the specification of which

☐ is attached hereto
OR
☒ was filed on 09/26/2003
as United States Application No. or PCT International Application No. 10/670,472
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign applications(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's right certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Application(s)			Priority Not	Certified Copy	
				YES	NO
_____	_____ (Country)	_____ (Filing Date)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Filing Date)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Filing Date)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional prior foreign applications are listed on a supplemental data sheet attached hereto.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor

Wenbin MA

Sole or first inventor's signature

Date

Residence

Brussels, Belgium

Citizenship Belgium

Mailing Address

Avenue Hippocrate 74

UCL 7459

B-1200 Brussels

BELGIUM

Full name of second inventor

Benoit VAN DEN EYNDE

Second inventor's signature

Date

April 8 2004

Residence

Brussels, Belgium

Citizenship Belgium

Mailing Address

Avenue Hippocrate 74

UCL 7459

B-1200 Brussels


BELGIUM

Full name of third inventor

Thierry BOON-FALLEUR

Third inventor's signature

Date 2- april 2004

 Boon Falleur

Residence

Brussels, Belgium

Citizenship Belgium

Mailing Address

Avenue Hippocrate 74

UCL 7459

B-1200 Brussels

BELGIUM

Full name of fourth inventor, if any

Catherine GERMEAU

Fourth inventor's signature

Date

Residence

Brussels, Belgium

Citizenship Belgium

Mailing Address

Avenue Hippocrate 74

UCL 7459

B-1200 Brussels

BELGIUM

Full name of fifth inventor, if any

Pierre COULIE

Fifth inventor's signature

Date 26 april 2004



Residence

Brussels, Belgium

Citizenship Belgium

Mailing Address

Avenue Hippocrate 74

UCL 7459

B-1200 Brussels

BELGIUM



Declaration for Patent Application English Language Declaration		Attorney Docket No.	LUD 5780.2 US	
		First Named Inventor	Wenbin Ma	
		COMPLETE IF KNOWN:		
<input type="checkbox"/> Submitted with initial filing	<input checked="" type="checkbox"/> Submitted after initial filing (surcharge required 37 CFR 1.16(e))	Application No.	10/670,472	
		Filing Date	September 26, 2003	
		Art Unit	1645	
		Examiner	Not Yet Assigned	

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF

the specification of which

☐ is attached hereto
OR
☒ was filed on 09/26/2003
as United States Application No. or PCT International Application No. 10/670,472
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign applications(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's right certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Application(s)			Priority Not	Certified Copy	
				YES	NO
	(Country)	(Filing Date)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Filing Date)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Filing Date)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional prior foreign applications are listed on a supplemental data sheet attached hereto.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor

Wenbin MA

Sole or first inventor's signature

Wenbin Ma

Residence

Brussels, Belgium

Citizenship China

Mailing Address

Avenue Hippocrate 74

UCL 7459

B-1200 Brussels

BELGIUM

Date

May 9th, 2006

Full name of second inventor

Benoit VAN DEN EYNDE

Second inventor's signature

Date

Residence

Brussels, Belgium

Citizenship Belgium

Mailing Address

Avenue Hippocrate 74

UCL 7459

B-1200 Brussels

BELGIUM

Full name of third inventor Thierry BOON-FALLEUR Third inventor's signature	Date
Residence Brussels, Belgium Citizenship Belgium Mailing Address Avenue Hippocrate 74 UCL 7459 B-1200 Brussels BELGIUM	
Full name of fourth inventor, if any Catherine GERMEAU Fourth inventor's signature	Date
Residence Brussels, Belgium Citizenship Belgium Mailing Address Avenue Hippocrate 74 UCL 7459 B-1200 Brussels BELGIUM	
Full name of fifth inventor, if any Pierre COULIE Fifth inventor's signature	Date
Residence Brussels, Belgium Citizenship Belgium Mailing Address Avenue Hippocrate 74 UCL 7459 B-1200 Brussels BELGIUM	



STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Wenbin MA et al.

Application No./Patent No.: 10/670,472

Filed/Issue Date: September 26, 2003

Entitled: MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF

Ludwig Institute for Cancer Research

(Name of Assignee)

, a

Corporation

Type of Assignee, e.g., corporation, partnership, university, government agency, etc.

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or

2. ☐ an assignee of less than the entire right, title and interest.

The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____ , Frame _____ , or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____ , Frame _____ , or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____ , Frame _____ , or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____ , Frame _____ , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE]: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

June 18, 2004
Date

Edward J. McDermott, Esq.


Typed or printed name

Edward A. McDermott, Jr.

Signature

President

Title



Please type a plus sign (+) inside this box




PTO/SB/81 (02-01)
Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	10/670,472
Filing Date	September 26, 2003
First Named Inventor	Wenbin MA, et al.
Title	MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF
Group Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket No.	LUD 5780.2 US/10312064


I hereby appoint:

☐ Practitioners at Customer Number 
Customer Number
OR
☒ Practitioner(s) named below:
Customer Number Bar Code

Name	Registration Number	Name	Registration Number
Norman D. Hanson	30,946		
Mary Anne Schofield	36,669		
Mark E. Ungerman	32,070		
Michael J. Strauss	32,443		
Thomas Hahn	30,845		
Steven M. War	48,024		

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.
OR
☐ Practitioners at Customer Number 
Customer Number
OR
☐
Customer Number Bar Code

☒ Firm or Individual Name
Fulbright & Jaworski L.L.P.

Address	Market Square 801 Pennsylvania Avenue, N.W.				
City	Washington	State	D.C.	Zip	20004-2623
Country		Telephone	(202) 662-0200	Fax	202-662-4643

I am the:

☐ Applicant/Inventor.
☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name Edward A. McDermott, Esq.

Signature 

Date June 18, 2004

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required. See below*.

☐ *Total of 1 forms are submitted.